Personalis PSNL 深 沪
交易中 10-06 10:14:18 美东时间
16.20
-0.200
-1.22%
华盛通- 最 高17.64
- 今 开16.25
- 成交量 22.89万股
- 最 低 15.915
- 昨 收 16.40
- 总市值 73.62万
- 52周最高 18.89
- 市盈率 静 --
- 换手率 503.62%
- 52周最低 4.955
- 委 比 -88.74%
- 总股本 4.54万
- 历史最高 53.46
- 量 比 2.39
- 振 幅 10.52%
- 历史最低 0.8906
- 每 手 1
- 风险率 3.32%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Benzinga Bulls and Bears: IBM, Super Micro, Tesla
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
07-25 20:00
Tempus AI Makes Billion-Dollar Bet on the Future of Cancer Monitoring
Tempus AI acquires Personalis for $1.5B to target the $20B MRD cancer monitoring market. Get full deal details and analysis.
07-22 02:52
Tempus AI Slides as Investors Weigh $1.5 Billion Personalis Acquisition
Tempus AI stock falls after a $1.5 billion Personalis deal expands its reach in the $20 billion MRD market.
07-21 00:46
Needham Downgrades Personalis to Hold
Needham analyst Mike Matson downgrades Personalis (NASDAQ:PSNL) from Buy to Hold.
07-20 23:35
Personalis Achieves UK Conformity Assessed Designation For Its NeXT Personal Dx Test
This critical regulatory milestone enables the clinical use of Personalis’ ultrasensitive Minimal Residual Disease (MRD) detection technology across Great Britain, encompassing England, Wales, and Scotland.The UKCA
07-14 18:13
Personalis Highlights Cancer-Detection Data Across Multiple Tumor Types
Personalis, Inc. (NASDAQ:PSNL) today announced clinical data from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting establishing the clinical importance of ultrasensitive MRD detection across six solid
06-02 18:17
Personalis to Present New Cancer Detection Data at Major Oncology Conference
Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced that six clinical abstracts demonstrating the broad use of its NeXT Personal® test will be presented at the 2026
05-26 18:07
US Agency Broadens Coverage Of Personalis Breast Cancer Test
Personalis wins expanded Medicare coverage for NeXT Personal MRD test in breast cancer patients undergoing neoadjuvant therapy.
05-21 02:22
Earnings Scheduled For February 26, 2026
Companies Reporting Before The Bell • Enovis (NYSE:ENOV) is estimated to report...
02-26 19:11
Personalis Gets Medicare Coverage For Lung Cancer Surveillance Test
Personalis (PSNL) stock up in premarket on Medicare coverage for its NeXT Personal test for lung cancer surveillance.
02-10 22:18
